It has been shown that Chou-Fasman conformational parameters of amino acids, which reflect their ability to adopt a definite conformation within the peptide chain, change very regularly within the genetic code, arranged in the manner discussed recently by Siemion and Stefanowicz (1992a) (BioSystems 27, 77-84). Two mutually perpendicular C2 axes of pseudosymmetry appear in the center of the diagrams (between ACY and ACR threonine codons) presenting the changes of P alpha and P beta parameters. The left and right parts of diagrams superimpose on each other quite well when the symmetry operation involving a proper axis is performed. This phenomenon is due, in our opinion, to the regular arrangement of equivalent codons in the 'one-step mutation' ring formed by 64 triplets of the genetic code.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0303-2647(94)90016-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SSL-VQ: Vector-quantized variational autoencoders for semi-supervised prediction of therapeutic targets across diverse diseases.
Bioinformatics
January 2025
Department of Bioscience and Bioinformatics, Faculty of Computer Science and Systems Engineering, Kyushu Institute of Technology, Iizuka, Fukuoka 820-8502, Japan.
Motivation: Identifying effective therapeutic targets poses a challenge in drug discovery, especially for uncharacterized diseases without known therapeutic targets (e.g. rare diseases, intractable diseases).
View Article and Find Full Text PDFSelection of initiator tRNA and start codon by mammalian mitochondrial initiation factor 3 in leaderless mRNA translation.
Nucleic Acids Res
January 2025
Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 5-1-5, Kashiwanoha, Kashiwa-shi, Chiba 277-8562, Japan.
Article Synopsis
- The mammalian mitochondrial protein synthesis system is responsible for synthesizing 13 crucial subunits for energy production, but the exact role of IF-3mt in translation initiation is still unclear.
- Researchers created a mitochondrial translation system to explore IF-3mt's proofreading abilities, revealing it helps distinguish between different start codons for more accurate protein synthesis.
- The findings indicate that IF-3mt not only supports initiation from standard AUG start codons but can also facilitate initiation from non-AUG codons like AUA, highlighting its adaptability in working with leaderless mRNAs.
Naxos disease is a rare autosomal recessive condition combining arrhythmogenic right ventricular cardiomyopathy, woolly hair, and palmoplantar keratoderma. The first identified causative variant was in the gene encoding the desmosomal protein plakoglobin. Naxos disease exhibits fibro-fatty myocardial replacement with immunohistological abnormalities in cardiac protein and signaling pathways, highlighting the role of inflammation and potential anti-inflammatory treatments.
View Article and Find Full Text PDFIndividualized Neoantigen-Directed Melanoma Therapy.
Am J Clin Dermatol
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
Individualized neoantigen-directed therapy represents a groundbreaking approach in melanoma treatment that leverages the patient's own immune system to target cancer cells. This innovative strategy involves the identification of unique immunogenic neoantigens (mutated proteins specific to an individual's tumor) and the development of therapeutic vaccines that either consist of peptide sequences or RNA encoding these neoantigens. The goal of these therapies is to induce neoantigen-specific immune responses, enabling the immune system to recognize and destroy cancer cells presenting the targeted neoantigens.
View Article and Find Full Text PDFMolecular Therapeutics in Development to Treat Hyperlipoproteinemia.
Mol Diagn Ther
January 2025
Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, 4288A-1151 Richmond Street North, London, ON, N6A 5B7, Canada.
Clinical endpoints caused by hyperlipoproteinemia include atherosclerotic cardiovascular disease and acute pancreatitis. Emerging lipid-lowering therapies targeting proprotein convertase subtilisin/kexin 9 (PCSK9), lipoprotein(a), apolipoprotein C-III, and angiopoietin-like protein 3 represent promising advances in the management of patients with hyperlipoproteinemia. These therapies offer novel approaches for lowering pathogenic lipid and lipoprotein species, particularly in patients with serious perturbations who are not adequately controlled with conventional treatments or who are unable to tolerate them.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!